GRCE Stock Overview
Engages in the development and commercialization of pharmaceutical products for rare and orphan diseases in Canada.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
+ 1 more risk
Grace Therapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$3.14 |
| 52 Week High | US$3.60 |
| 52 Week Low | US$1.98 |
| Beta | 1.52 |
| 11 Month Change | 0.80% |
| 3 Month Change | 24.40% |
| 1 Year Change | 27.37% |
| 33 Year Change | -69.26% |
| 5 Year Change | -96.43% |
| Change since IPO | -99.47% |
Recent News & Updates
Recent updates
Will Acasti Pharma (NASDAQ:ACST) Spend Its Cash Wisely?
Sep 02
We're Keeping An Eye On Acasti Pharma's (NASDAQ:ACST) Cash Burn Rate
Apr 20Will Acasti Pharma (NASDAQ:ACST) Spend Its Cash Wisely?
Nov 14We're Not Very Worried About Acasti Pharma's (NASDAQ:ACST) Cash Burn Rate
May 10Acasti Pharma GAAP EPS of -$0.10
Aug 11Acasti inks deal for Grace Therapeutics, shares surge
May 07Acasti Pharma issues clarification on trading activity
Dec 23Acasti Pharma EPS in-line
Nov 16Shareholder Returns
| GRCE | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | -2.3% | -3.7% | -1.6% |
| 1Y | 27.4% | 17.2% | 30.8% |
Return vs Industry: GRCE exceeded the US Pharmaceuticals industry which returned 17.2% over the past year.
Return vs Market: GRCE underperformed the US Market which returned 30.8% over the past year.
Price Volatility
| GRCE volatility | |
|---|---|
| GRCE Average Weekly Movement | 10.1% |
| Pharmaceuticals Industry Average Movement | 9.3% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 14.9% |
| 10% least volatile stocks in US Market | 2.9% |
Stable Share Price: GRCE's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: GRCE's weekly volatility (10%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2002 | n/a | Prashant Kohli | www.acastipharma.com |
Grace Therapeutics, Inc. engages in the development and commercialization of pharmaceutical products for rare and orphan diseases in Canada. The company’s lead product candidate is the GTX-104, an intravenous infusion to treat subarachnoid hemorrhage. It also develops GTX-102, an oral mucosal betamethasone spray for the treatment of ataxia-telangiectasia; and GTX-101, a topical bioadhesive film-forming bupivacaine spray for postherpetic neuralgia.
Grace Therapeutics, Inc. Fundamentals Summary
| GRCE fundamental statistics | |
|---|---|
| Market cap | US$31.43m |
| Earnings (TTM) | -US$11.45m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-2.8x
P/E RatioIs GRCE overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| GRCE income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$11.45m |
| Earnings | -US$11.45m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.13 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did GRCE perform over the long term?
See historical performance and comparison